LCM
KITE

Legato Capital Management’s Kite Pharma, Inc. KITE Stock Holding History

Legato Capital Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,839
Closed -$294K – 296
2017
Q2 		$294K Buy
+2,839
New +$232K 0.13% 174

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legato Capital Management's KITE Position: Q3 2017 in Review

Legato Capital Management sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 2,839 shares — an estimated $294K sold.

Legato Capital Management first reported a position in KITE in Q2 2017 and held it in 1 quarter. The position peaked at $294K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Legato Capital Management reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Legato Capital Management sold 2,839 Kite Pharma, Inc. shares in Q3 2017, an estimated $294K.
  • Legato Capital Management first reported a position in Kite Pharma, Inc. in Q2 2017 and held it in 1 quarter.
  • Legato Capital Management's Kite Pharma, Inc. position peaked at $294K in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Legato Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.